ReviewSN comprehensive clinical medicine2020
Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.
Review in SN comprehensive clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06364527 (Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma: A Pilot Study
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of corticosteroids on Covid-19 patients: A systematic review and meta-analysis on clinical outcomes.Pulmonary pharmacology & therapeutics · 2022Pooled it
- Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.BMJ open gastroenterology · 2021Pooled it
- Incorporating preprints in systematic reviews: a preliminary study of a novel method for rapid evidence synthesis.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- Defining the Differential Corticosteroid Response Basis from Multiple Omics Approaches.International journal of molecular sciences · 2024Review
- Potential Drugs in COVID-19 Management.Current medicinal chemistry · 2024Review
- Evaluation of Chronic Rhinosinusitis Symptoms' Severity Following COVID-19 Infection: A Retrospective Analysis.Cureus · 2023Article
- Comparison of Different Antiviral Regimens in the Treatment of Patients with Severe COVID-19: A Retrospective Cohort.Medicina (Kaunas, Lithuania) · 2023Article
- Pharmacometrics: A New Era of Pharmacotherapy and Drug Development in Low- and Middle-Income Countries.Advances in pharmacological and pharmaceutical sciences · 2023Review
- Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.Inflammopharmacology · 2022Review
- A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.European journal of clinical investigation · 2022Review
- Corticosteroids for COVID-19: worth it or not?Molecular biology reports · 2022Review
- Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- COVID-19 among African Americans and Hispanics: Does gastrointestinal symptoms impact the outcome?World journal of clinical cases · 2021Article
- Scientific evidence in the COVID-19 treatment: A comprehensive review.World journal of virology · 2021Review
- Corticosteroids for COVID-19.Journal of intensive medicine · 2021Review
- NF-κB signalling as a pharmacological target in COVID-19: potential roles for IKKβ inhibitors.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- Systemic Corticosteroid Administration in Coronavirus Disease 2019 Outcomes: An Umbrella Meta-Analysis Incorporating Both Mild and Pulmonary Fibrosis-Manifested Severe Disease.Frontiers in pharmacology · 2021Review
- Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?Journal of personalized medicine · 2020Article
- Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to a lack of definitive treatment, many drugs were repurposed for Coronavirus disease (COVID-19) treatment; among them, corticosteroid is one. However, its benefit or harm while treating COVID-19 is not fully studied. Thus, we conducted this meta-analysis to assess the rationality on the use of corticosteroids in COVID-19. Pubmed, Medline, Clinicaltrials.gov, Cochrane library, and Preprint publisher were searched. In the qualitative syntheses, 41, and quantitative studies, 40, were included using PRISMA guidelines. Assessment of heterogeneity was done using the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.